Skip to main content
Clinical Trials/NCT04624490
NCT04624490
Recruiting
Phase 1

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Mario Castro, MD, MPH1 site in 1 country260 target enrollmentNovember 2, 2020

Overview

Phase
Phase 1
Intervention
Hyperpolarized Xe129
Conditions
Asthma
Sponsor
Mario Castro, MD, MPH
Enrollment
260
Locations
1
Primary Endpoint
RBC/Barrier Ratio
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

Detailed Description

This is an unblinded, open-label study with \~160 subjects with diagnosed pulmonary disease and \~100 healthy controls. Subjects to be enrolled will include males and females 18-80 years old. Evaluation will be on an outpatient basis. Imaging will be done on a single day and will involve administration of up to four 1-liter doses of HP 129Xe plus one 129Xe calibration dose (\~300-400mL HP 129Xe). In addition to 129Xe MRI, a series of anatomical conventional 1H MR images will be collected including a localizer scan, breath-hold spin echo image, and breath-hold steady-state free precession image to highlight the vasculature. All subjects will be evaluated at one center: The University of Kansas Medical Center, KS USA.

Registry
clinicaltrials.gov
Start Date
November 2, 2020
End Date
October 26, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Mario Castro, MD, MPH
Responsible Party
Sponsor Investigator
Principal Investigator

Mario Castro, MD, MPH

Division Chief, Pulmonary, Critical Care and Sleep Medicine

University of Kansas Medical Center

Eligibility Criteria

Inclusion Criteria

  • Healthy Volunteers:
  • Subject has no diagnosed pulmonary conditions
  • Ability to read and understand English or Spanish
  • Subjects with Lung Disease:
  • Subject has a diagnosis of pulmonary dysfunction made by a physician
  • No acute worsening of pulmonary function in the past 30 days
  • Ability to read and understand English or Spanish

Exclusion Criteria

  • MRI is contraindicated based on responses to MRI screening questionnaire
  • Subject is pregnant or lactating
  • Subject does not fit into 129Xe vest coil used for MRI
  • Subject cannot hold his/her breath for 15-16 seconds
  • Subject deemed unlikely to be able to comply with instructions during imaging
  • Oxygen saturation \<88% on room air or with supplemental oxygen
  • Cognitive deficits that preclude ability to provide consent
  • Institutionalization

Arms & Interventions

Hyperpolarized 129Xe

Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.

Intervention: Hyperpolarized Xe129

Outcomes

Primary Outcomes

RBC/Barrier Ratio

Time Frame: Day 1

Ratio of xenon signal dissolved in RBCs to xenon signal dissolved in Barrier Tissues

Secondary Outcomes

  • ADC(Day 1)
  • Ventilation Defect Percentage(Day 1)

Study Sites (1)

Loading locations...

Similar Trials